{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T19:00:30Z","timestamp":1761418830634,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.hlc.2012.06.013","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T20:46:53Z","timestamp":1342817213000},"page":"671-678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Changes in Exercise Capacity and Cardiac Performance in a Series of Patients with Eisenmenger's Syndrome Transitioned from Selective to Dual Endothelin Receptor Antagonist"],"prefix":"10.1016","volume":"21","author":[{"given":"Grzegorz","family":"Kope\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tyrka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Miszalski-Jamka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Miko\u0142ajczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Walig\u00f3ra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Guzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Podolec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2012.06.013_bib0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/thx.2004.031724","article-title":"The endothelin system and its role in pulmonary arterial hypertension (PAH)","volume":"60","author":"Pepke-Zaba","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.hlc.2012.06.013_bib0010","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1111\/j.1755-5922.2010.00158.x","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension: an overview","volume":"28","author":"Raja","year":"2010","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.hlc.2012.06.013_bib0015","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","article-title":"Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension","volume":"120","author":"Rubens","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.hlc.2012.06.013_bib0020","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/ajrccm.165.3.2104059","article-title":"ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells","volume":"165","author":"Davie","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hlc.2012.06.013_bib0025","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000102534","article-title":"Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions","volume":"44","author":"Sauvageau","year":"2007","journal-title":"J Vasc Res"},{"key":"10.1016\/j.hlc.2012.06.013_bib0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/pupt.2000.0242","article-title":"Importance of local production of endothelin-1 and of the ET(B) receptor in the regulation of pulmonary vascular tone","volume":"13","author":"Dupuis","year":"2000","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.hlc.2012.06.013_bib0035","first-page":"L358","article-title":"Chronic hypoxia augments endothelin-B receptor-mediated vasodilation in isolated perfused rat lungs","volume":"276","author":"Muramatsu","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.hlc.2012.06.013_bib0040","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2459\/01.JCM.0000242996.19077.ba","article-title":"Effect of endothelins on the cardiovascular system","volume":"7","author":"Penna","year":"2006","journal-title":"J Cardiovasc Med"},{"key":"10.1016\/j.hlc.2012.06.013_bib0045","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1517\/14656566.2011.564159","article-title":"Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension","volume":"12","author":"O\u2019Callaghan","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.hlc.2012.06.013_bib0050","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.hlc.2010.07.005","article-title":"Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21","volume":"19","author":"Kermeen","year":"2010","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2012.06.013_bib0055","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2012.06.013_bib0060","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0195-668X(03)00131-3","article-title":"Management of grown up congenital heart disease","volume":"24","author":"Deanfield","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2012.06.013_bib0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hlc.2012.06.013_bib0070","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jacc.2006.10.056","article-title":"Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction","volume":"49","author":"Larose","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2012.06.013_bib0075","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jcmg.2010.09.018","article-title":"Extent of RV dysfunction and myocardial infarction assessed by CMR are independent outcome predictors early after STEMI treated with primary angioplasty","volume":"3","author":"Miszalski-Jamka","year":"2010","journal-title":"JACC Cardiovasc Imag"},{"key":"10.1016\/j.hlc.2012.06.013_bib0080","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1161\/01.CIR.0000095268.47282.A1","article-title":"Practical value of cardiac magnetic resonance imaging for clinical quantification of aortic valve stenosis: comparison with echocardiography","volume":"108","author":"Caruthers","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2012.06.013_bib0085","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2011.01217.x","article-title":"Role of the endothelin axis and its antagonists in the treatment of cancer","volume":"163","author":"Bagnato","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.hlc.2012.06.013_bib0090","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1532-429X-14-6","article-title":"Cardiovascular magnetic resonance in pulmonary hypertension","volume":"14","author":"Bradlow","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.hlc.2012.06.013_bib0095","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hlc.2012.06.013_bib0100","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1136\/hrt.2005.085118","article-title":"Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension","volume":"92","author":"van Wolferen","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.hlc.2012.06.013_bib0105","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jacc.2010.08.648","article-title":"Right ventricular failure following chronic pressure overload is associated with reduction in left ventricular mass evidence for atrophic remodeling","volume":"22","author":"Hardziyenka","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2012.06.013_bib0110","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1161\/HYPERTENSIONAHA.109.148569","article-title":"Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men","volume":"55","author":"MacIntyre","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.hlc.2012.06.013_bib0115","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jjcc.2009.01.002","article-title":"Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension","volume":"53","author":"Hiramoto","year":"2009","journal-title":"J Cardiol"},{"key":"10.1016\/j.hlc.2012.06.013_bib0120","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.92.3.357","article-title":"Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo","volume":"92","author":"Haynes","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2012.06.013_bib0125","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/hc0902.105719","article-title":"Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension","volume":"105","author":"Bauer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2012.06.013_bib0130","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1161\/01.CIR.0000094397.19932.78","article-title":"Endothelin receptor blockers in cardiovascular disease","volume":"108","author":"Rich","year":"2003","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.hlc.2012.06.013_bib0135","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1097\/01.fjc.0000166230.26583.f8","article-title":"Upregulation of vascular ET(B) receptor gene expression after chronic ET(A) receptor blockade in prediabetic NOD mice","volume":"44","author":"Ortmann","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hlc.2012.06.013_bib0140","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2012.06.013_bib0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijcard.2007.04.078","article-title":"Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study","volume":"127","author":"Gatzoulis","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2012.06.013_bib0150","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1185\/030079906X158020","article-title":"Endothelin receptor antagonism in pulmonary arterial hypertension\u2014a role for selective ET(A) inhibition?","volume":"22","author":"Jacobs","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.hlc.2012.06.013_bib0155","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.rmed.2010.08.003","article-title":"Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature","volume":"104","author":"Swiston","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.hlc.2012.06.013_bib0160","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/ajrccm.161.2.9906015","article-title":"Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing","volume":"161","author":"Miyamoto","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hlc.2012.06.013_bib0165","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2012.06.013_bib0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.amjcard.2004.03.081","article-title":"Initial experience with bosentan therapy in patients with the Eisenmenger syndrome","volume":"94","author":"Christensen","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hlc.2012.06.013_bib0175","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/hrt.2004.051961","article-title":"Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease","volume":"91","author":"Apostolopoulou","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.hlc.2012.06.013_bib0180","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jcmg.2010.09.013","article-title":"Imaging in pulmonary hypertension","volume":"3","author":"Lang","year":"2010","journal-title":"JACC Cardiovasc Imag"},{"key":"10.1016\/j.hlc.2012.06.013_bib0195","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1253\/circj.CJ-11-1517","article-title":"Electrocardiogram for the diagnosis of right ventricular hypertrophy and dilation in idiopathic pulmonary arterial hypertension","volume":"76","author":"Kopec","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.hlc.2012.06.013_bib0190","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","article-title":"Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial","volume":"31","author":"Iversen","year":"2010","journal-title":"Eur Heart J"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950612010979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950612010979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T17:58:37Z","timestamp":1761415117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950612010979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1443950612010979"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2012.06.013","relation":{},"ISSN":["1443-9506"],"issn-type":[{"type":"print","value":"1443-9506"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in Exercise Capacity and Cardiac Performance in a Series of Patients with Eisenmenger's Syndrome Transitioned from Selective to Dual Endothelin Receptor Antagonist","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2012.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}